915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Saved in:
| Title: | 915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). |
|---|---|
| Authors: | Greil, R.1 (AUTHOR), Rischin, D.2 (AUTHOR), Harrington, K.J.3 (AUTHOR), Soulières, D.4 (AUTHOR), Tahara, M.5 (AUTHOR), de Castro, G.6 (AUTHOR), Psyrri, A.7 (AUTHOR), Baste, N.8 (AUTHOR), Neupane, P.9 (AUTHOR), Bratland, Å.10 (AUTHOR), Fuereder, T.11 (AUTHOR), Hughes, B.G.M.12 (AUTHOR), Mesia, R.13 (AUTHOR), Ngamphaiboon, N.14 (AUTHOR), Rordorf, T.15 (AUTHOR), Ishak, W.Z. Wan16 (AUTHOR), Lin, J.17 (AUTHOR), Swaby, R.F.17 (AUTHOR), Gumuscu, B.17 (AUTHOR), Burtness, B.18 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS660-S661. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.1030 |
